Nancy J Brown Selected Research

N- ((4- cyano- 2- (trifluoromethyl)phenyl)methyl)- 3- ((4- methyl- 6- (methylamino)- 1,3,5- triazin- 2- yl)amino)cyclohexanecarboxamide

1/2021

GSK2256294 Decreases sEH (Soluble Epoxide Hydrolase) Activity in Plasma, Muscle, and Adipose and Reduces F2-Isoprostanes but Does Not Alter Insulin Sensitivity in Humans.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nancy J Brown Research Topics

Disease

41	Hypertension (High Blood Pressure) 01/2021 - 03/2002
14	Insulin Resistance 01/2021 - 08/2002
13	Angioedema 12/2020 - 02/2002
12	Inflammation (Inflammations) 01/2022 - 05/2005
12	Fibrosis (Cirrhosis) 01/2019 - 05/2002
11	Heart Failure 01/2022 - 05/2003
11	Cardiovascular Diseases (Cardiovascular Disease) 11/2018 - 10/2005
9	Type 2 Diabetes Mellitus (MODY) 01/2021 - 05/2012
8	Thrombosis (Thrombus) 11/2018 - 12/2003
7	Atrial Fibrillation 01/2018 - 09/2007
6	Obesity 01/2018 - 02/2004
6	Metabolic Syndrome (Dysmetabolic Syndrome X) 09/2017 - 09/2007
5	Myocardial Infarction 11/2018 - 12/2002
5	Essential Hypertension 12/2011 - 03/2002
4	Hyperglycemia 01/2018 - 02/2004
4	Acute Kidney Injury (Acute Renal Failure) 07/2016 - 12/2010
3	Hypotension (Low Blood Pressure) 10/2012 - 11/2005
3	Albuminuria 09/2012 - 09/2007
3	Body Weight (Weight, Body) 05/2012 - 02/2004
3	Vascular Remodeling 10/2010 - 06/2002
3	Edema (Dropsy) 09/2010 - 08/2007
2	Chronic Kidney Failure (Chronic Renal Failure) 11/2021 - 10/2015
2	Hyperaldosteronism (Conn Syndrome) 01/2021 - 09/2007
2	Pathologic Processes 01/2020 - 09/2005
2	Hemorrhage 11/2018 - 01/2011
2	Hypertriglyceridemia 11/2018 - 10/2016
2	Diabetes Mellitus 01/2018 - 08/2014
2	Prediabetic State (Prediabetes) 01/2018 - 12/2015
2	Drug-Related Side Effects and Adverse Reactions 09/2017 - 09/2013
2	Chronic Renal Insufficiency 01/2017 - 03/2016
2	Ischemia 01/2017 - 05/2012
2	Amyloidosis 12/2014 - 07/2014
2	Heart Diseases (Heart Disease) 08/2013 - 01/2011
2	Weight Gain 04/2013 - 05/2012

Drug/Important Bio-Agent (IBA)

19	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 12/2020 - 02/2002
17	Plasminogen Activator Inhibitor 1IBA 01/2017 - 05/2002
16	AldosteroneIBA 10/2014 - 05/2002
15	SaltsIBA 07/2014 - 03/2004
12	Plasminogen Activators (Plasminogen Activator)IBA 01/2017 - 05/2002
11	Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA 01/2019 - 05/2002
11	Glucose (Dextrose)FDA LinkGeneric 01/2018 - 10/2004
11	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 07/2017 - 04/2004
10	BradykininIBA 11/2018 - 02/2002
7	Substance PIBA 01/2017 - 02/2002
7	SodiumIBA 03/2016 - 03/2002
6	AcidsIBA 01/2022 - 10/2014
6	Sitagliptin Phosphate (Januvia)FDA Link 01/2021 - 10/2010
6	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2021 - 09/2009
6	Peptides (Polypeptides)IBA 01/2020 - 11/2006
6	Pharmaceutical PreparationsIBA 09/2017 - 09/2009
6	Proteins (Proteins, Gene)FDA Link 05/2016 - 10/2005
6	ReninIBA 10/2014 - 10/2004
6	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2012 - 06/2002
5	Epoxide HydrolasesIBA 01/2022 - 10/2014
5	EnzymesIBA 01/2022 - 03/2002
5	Angiotensin Receptor AntagonistsIBA 12/2020 - 09/2009
5	Ramipril (Altace)FDA LinkGeneric 10/2019 - 05/2009
5	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 10/2019 - 02/2002
5	Insulin (Novolin)FDA Link 01/2018 - 10/2004
5	Mineralocorticoid Receptor AntagonistsIBA 03/2016 - 05/2003
5	Spironolactone (Aldactone)FDA LinkGeneric 07/2014 - 05/2003
5	Angiotensin IIIBA 09/2012 - 05/2009
4	Biomarkers (Surrogate Marker)IBA 05/2015 - 09/2007
4	AngiotensinsIBA 07/2011 - 10/2003
3	F2-Isoprostanes (F2 Isoprostanes)IBA 01/2021 - 10/2003
3	Valsartan (Vals)FDA Link 10/2019 - 03/2007
3	Fish OilsIBA 11/2018 - 10/2013
3	Hypoglycemic Agents (Hypoglycemics)IBA 01/2018 - 05/2012
3	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 01/2018 - 10/2013
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 07/2016 - 12/2010
3	PotassiumIBA 08/2013 - 11/2006
3	Cytochrome P-450 CYP11B2 (CYP11B2)IBA 08/2013 - 05/2009
3	Messenger RNA (mRNA)IBA 09/2012 - 02/2004
3	Plasminogen InactivatorsIBA 04/2012 - 08/2002
3	2,5-dichloro-4-bromophenol (B 2)IBA 10/2009 - 11/2005
2	LipidsIBA 01/2022 - 01/2016
2	CatecholaminesIBA 01/2022 - 01/2020
2	sacubitril and valsartan sodium hydrate drug combinationIBA 11/2021 - 03/2016
2	Atorvastatin (Lipitor)FDA Link 01/2020 - 03/2016
2	Phospholipids (Phosphatides)FDA LinkGeneric 11/2018 - 10/2013
2	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 11/2018 - 01/2018
2	Vasodilator Agents (Vasodilators)IBA 01/2018 - 01/2018
2	icatibantIBA 07/2017 - 10/2009
2	Bradykinin B2 ReceptorIBA 07/2017 - 11/2005
2	Antihypertensive Agents (Antihypertensives)IBA 01/2017 - 11/2005
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2017 - 09/2002
2	HDL LipoproteinsIBA 10/2016 - 10/2004
2	Brain Natriuretic Peptide (Natrecor)FDA Link 07/2016 - 03/2016
2	Enalapril FDA LinkGeneric 03/2016 - 10/2010
2	Neprilysin (Neutral Endopeptidase)IBA 03/2016 - 09/2013
2	CreatinineIBA 03/2016 - 10/2004
2	Type 5 Cyclic Nucleotide PhosphodiesterasesIBA 12/2015 - 05/2009
2	Dietary SodiumIBA 10/2014 - 11/2006
2	Glucagon-Like Peptide 1 (GLP 1)IBA 08/2014 - 05/2012
2	Cytochrome P-450 CYP4A (Alkane 1 Monooxygenase)IBA 07/2014 - 08/2008

Therapy/Procedure

5	Renal Dialysis (Hemodialysis) 01/2020 - 10/2009
4	Cardiopulmonary Bypass (Heart-Lung Bypass) 01/2017 - 11/2005
3	Therapeutics 01/2018 - 12/2010
2	Sodium-Restricted Diet (Diet, Sodium Restricted) 10/2014 - 07/2011
2	Length of Stay 10/2012 - 09/2007